HealthcareMid capRs 15,502 crRs 18.7 cr traded a dayHealthcare
Close on 10 September 2026
384.00
−0.72%
52-week range0% of the way up
384.00663.85
Market cap
15,502 cr
P/E (TTM)
54.4×
industry 45×
EPS (TTM)
7.06
Revenue YoY
-6.8%
Q1 FY27
Profit YoY
-111.9%
Net margin
-1.2%
-10.8pt vs a year ago
Growth trend
-19.8pt
vs last quarter’s YoY
1 month
-6.0%
Below 52w high
72.9%
RSI (14)
31
Daily swing
2.3%
average true range
Volume
0.4×
vs 20-day average
Traded
Rs 19 cr
median day
Close200-day averageMaterial filing
260 sessions · hover for the filing behind a move
Key metrics
each ranked against every stock scanned tonight
Above the 200-day average
Bottom of the universe
-17.6%
One-year return
Bottom of the universe
-41.4%
Return on capital employed
Below the median
8.0%
Debt to equity
Above the median
0.00×
Profitable quarters, last four
of the last four reported
3 of 4
Cash conversion
cash from operations against reported profit
321%
Revenue growth, year on year
latest reported quarter
-6.8%
Below the 52-week high
from the highest close of the year
-42.2%
1 week
−4.19%
1 month
−6.03%
3 months
−15.33%
6 months
−8.54%
1 year
−41.40%
The read
written from the numbers on this page
The evidence leans negative1 supporting, 6 against, 0 worth knowing
Supporting
matches near a 52-week low, which has beaten the market by +0.38 points over 20 sessions across 48,405 past signals
Against
trading 18% below its 200-day average
at 0% of its 52-week range — nearly everyone who bought in the past year is underwater
down 41% over twelve months
revenue fell 7% year on year in the quarter ending 30 June 2026
net margin has narrowed from 13.9% to -1.2% across four quarters
priced at 54× earnings against an industry median of 45× — 22% above its peers
Worth knowing
nothing the data supports either way
SYNGENE sits in Healthcare — worth checking whether the whole group is moving together or whether this name is doing it alone.
What would change this read: a close back above 466, its 200-day average.
Assembled automatically from the figures on this page — the scans matched, their measured record, the filed financials, the derivatives positioning and the peer comparison. It is not a recommendation, no one has spoken to the company, and every claim above can be checked against a number further down this page.
What is working, what is not
from the filings and from the price, with the figure behind every line
Working3
Syngene International holds Rs 229 cr cash against Rs 9 cr borrowings, showing a strong net cash position.
Rs 229 crRs 9 cr
Operating cash flow was Rs 915 cr against Rs 285 cr profit, which is 321% of it.
Rs 915 crRs 285 cr321%
Borrowings are 0.00 times owners' equity, with Rs 9 cr debt against Rs 4,839 cr equity.
0.00Rs 9 crRs 4,839 cr
Needs watching8
Net profit -108.5% year on year, Rs 106 cr to Rs -9 cr.
-108.5%Rs 106 crRs -9 cr
Profit growth was -108.5%, while revenue growth was -17.4%, indicating profit grew slower than revenue.
-108.5%-17.4%
Net margin fell from 11.9% to -1.2% in the same quarter last year.
11.9%-1.2%
Trading 17.6% below its 200-day average.
-17.6%
42% below its 52-week high.
-42%
Only 0.0% above its 52-week low.
+0.0%
Down 41.4% over the past year.
-41.4%
A warning rule fires on it tonight: near a 52-week low.
Near a 52-week low
Every figure here is computed — from the company’s own filings, or from its own closing prices. Wording of 5 of these 6 filing lines was drafted by a language model, which is given the figures and may not introduce another — any sentence containing a number that did not come from the filings is discarded before it reaches this page.
How it has performed
price return over each window, beside the median NSE stock over the same days
What the scans say today
1 of 47 matched on 10 Sep
SYNGENE matches 1 of the 47 scans today, across 1 different kinds of evidence.
Return on capital uses profit before tax over equity plus borrowings. The textbook version adds finance costs back; those are not tagged reliably in quarterly filings, so this understates the ratio for a heavily borrowed company rather than flattering it. Balance sheets are filed half-yearly, so these can be up to six months behind the profit figures above.
Valuation against its own history
500 sessions since 26 September 2024
44×
median 53×
73×
now 54×
SYNGENE trades at 54× trailing earnings, close to its median of 53× over this window. The band runs from the 5th to the 95th percentile, so single-day spikes do not set the edges.
This window is short by the standards of valuation history — it begins where four quarters of filed earnings first exist. A stock can look cheap against two years and expensive against ten.
Analyst call filings were typically +0.11pt vs the market over the next 5 sessions (n=4,339) · Other filing filings were typically +0.01pt vs the market over the next 5 sessions (n=17,202)
The business
from the company’s filed results
Everything below is taken from the company’s own quarterly filing with the exchange — the XBRL document it submitted, not a vendor’s summary of it. Figures in rupees crore.
RevenueNet profit, drawn inside its revenue barNet margin, own scale belowrupees crore, per quarter as filed. Revenue bars start at zero.
Going for it
nothing clear in the filed numbers
Going against it
revenue fell 7% against the same quarter a year earlier
profit dropped 112% year on year
net margin narrowed from 14.3% to -1.2%
Quarter-by-quarter numbers, as filed
Quarter
Revenue
Profit before tax
Net profit
EPS
Net margin
Q1 FY27
30 Jun · consolidated
736
-19
-9
—
-1.2%
Q4 FY26
31 Mar · consolidated
1,036
196
148
3.68
14.3%
Q3 FY26
31 Dec · consolidated
917
28
15
0.37
1.6%
Q3 FY25
31 Dec · consolidated
944
181
131
3.27
13.9%
Q2 FY25
30 Sep · consolidated
891
137
106
2.64
11.9%
Q1 FY25
30 Jun · consolidated
790
101
76
1.89
9.6%
Quarterly filings are unaudited unless stated. Consolidated figures are used where the company files both. A single quarter is a noisy thing — the trend across the column is worth more than the top row.
Where the price stands
the same figures every scan on this site is computed from
Trend
Distance from the averages traders watch. Above all of them is a bull phase; below the 200-day is the line most investors use to say otherwise.
Versus 50-day average-5.6%
Versus 200-day average-17.6%
Below 52-week high-42.2%
Above 52-week low+0.0%
Momentum
How hard it has been pushed lately. Above 70 on RSI is stretched, below 30 is washed out — neither is a signal on its own.
RSI (14)30.9
Higher closes in last 50 of 5
Six-month return−8.54%
Risk and liquidity
What a position costs to hold and to exit. Position sizing starts with the daily swing, not with conviction.
Typical daily swing (ATR)2.34%
Volume versus 20-day0.4x
Median daily turnoverRs 18.7 cr
Peers
Healthcare · 68 classified companies
SYNGENE trades at 54.4× trailing earnings against an industry median of 44.7× across 65 other classified companies in its industry — more expensive than them, by 22%. A multiple is a statement about expectations, not about quality: cheap usually means the market expects less, and it is often right.
largest twelve by market capitalisation. Market cap and P/E need filed financials, so blanks are companies whose filings have not been read yet
Recent sessions
what this stock has matched since the engine went live
This is the live record, not the backtest — the scans this stock actually appeared in on each stored session. A name that keeps reappearing is in a persistent condition; a one-day appearance usually is not.